Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...

Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs

Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs

A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in determining the metabolic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pain Control, Glucose Control, and Quality of Life in Patients With Chronic Pancreatitis After Total Pancreatectomy With Islet Autotransplantation: A Preliminary Report.

Transplantation proceedings·2017

Same author

External Validation of the Newly Developed BETA-2 Scoring System for Pancreatic Islet Graft Function Assessment.

Transplantation proceedings·2017

Same author

Patients with KCNJ11-related diabetes frequently have neuropsychological impairments compared with sibling controls.

Diabetic medicine : a journal of the British Diabetic Association·2016

Same author

Resting beta-cells - A functional reserve?

Diabetes & metabolism·2016

Same author

Ion channels and regulation of insulin secretion in human β-cells: a computational systems analysis.

Islets·2013

Same author

Genome wide association studies for diabetes: perspective on results and challenges.

Pediatric diabetes·2013

Search research articles

Related Experiment Video

Updated: May 12, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

beta-Agonists and metabolism.

L H Philipson¹

¹Department of Medicine, University of Chicago, Chicago, IL 60637, USA. l-philipson@uchicago.edu

The Journal of Allergy and Clinical Immunology

|December 5, 2002

Summary

Beta-agonists influence glucose homeostasis by affecting insulin secretion and liver metabolism. Hypoglycemia can reduce beta-agonist sensitivity, but avoidance can restore it, aiding diabetes management.

Area of Science:

Endocrinology
Metabolic Regulation
Pharmacology

Background:

Beta-agonists impact glucose homeostasis through insulin secretion, liver metabolism, and muscle glucose uptake.
The interplay between hypoglycemia and beta-agonist sensitivity is crucial for diabetes management.
Beta-adrenergic receptor (beta-AR) polymorphisms, particularly in beta(3)AR, influence adipocyte metabolism.

Purpose of the Study:

To review current understanding of how beta-agonists affect glucose homeostasis.
To examine the influence of hypoglycemia on beta-agonist sensitivity.
To discuss the role of beta(3)-adrenergic receptor polymorphisms in metabolic regulation.

Main Methods:

Literature review of recent concepts and human studies.
Analysis of beta(2)-agonist effects on pancreatic beta cells and hepatic metabolism.

More Related Videos

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Arteriovenous Metabolomics to Measure In Vivo Metabolite Exchange in Brown Adipose Tissue

Arteriovenous Metabolomics to Measure In Vivo Metabolite Exchange in Brown Adipose Tissue

Published on: October 6, 2023

Related Experiment Videos

Last Updated: May 12, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Arteriovenous Metabolomics to Measure In Vivo Metabolite Exchange in Brown Adipose Tissue

Arteriovenous Metabolomics to Measure In Vivo Metabolite Exchange in Brown Adipose Tissue

Published on: October 6, 2023

Investigation of beta-agonist roles in thermogenesis, lipolysis, and energy expenditure.

Main Results:

Beta(2)-agonists stimulate insulin secretion but can increase serum glucose via glucagon and hepatic effects, reducing apparent insulin sensitivity.
Intensive diabetes treatment increases hypoglycemia risk, leading to reduced beta-agonist sensitivity and impaired hypoglycemia detection.
Restoring beta-agonist sensitivity is possible through consistent hypoglycemia avoidance, improving glucose awareness.

Conclusions:

Beta-agonists have complex effects on glucose homeostasis, balancing insulin secretion with counter-regulatory mechanisms.
Hypoglycemia significantly impacts beta-agonist sensitivity, posing challenges for diabetes therapy.
Beta-adrenergic receptors, including beta(3)AR, play a role in adipocyte metabolism, with implications for obesity and metabolic syndrome.